Evidence map›Paper›PMID 33166402›Full record

ArticleBlood advances2020

Processing methods and storage duration impact extracellular vesicle counts in red blood cell units.

Clementine Gamonet, Maxime Desmarets, Guillaume Mourey, Sabeha Biichle, Sophie Aupet, Caroline Laheurte, Anne François, Eric Resch, Frédéric Bigey, Delphine Binda and 11 more

Open access · goldAbstract read
In one paragraph

Article in Blood advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 41 citations in OpenAlex.

  1. Article
  2. Engineering platelets as cancer therapeutics.Nature reviews. Clinical oncology · 2026
    Review
  3. Article
  4. Red Blood Cell Storage and Post-transfusion Recovery.Methods in molecular biology (Clifton, N.J.) · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 4 institutions in 2 countries.

Clementine GamonetUniversity Bourgogne Franche-Comté, INSERM, Etablissement Français du sang Bourgogne Franche Comté, Unité Mixte de Recherche 1098, Interactions Hôte-Greffon-Tumeur, Ingénierie Cellulaire et Génique, Besançon, France.
Maxime DesmaretsUniversity Bourgogne Franche-Comté, INSERM, Etablissement Français du sang Bourgogne Franche Comté, Unité Mixte de Recherche 1098, Interactions Hôte-Greffon-Tumeur, Ingénierie Cellulaire et Génique, Besançon, France.
Guillaume MoureyUniversity Bourgogne Franche-Comté, INSERM, Etablissement Français du sang Bourgogne Franche Comté, Unité Mixte de Recherche 1098, Interactions Hôte-Greffon-Tumeur, Ingénierie Cellulaire et Génique, Besançon, France.
Sabeha BiichleUniversity Bourgogne Franche-Comté, INSERM, Etablissement Français du sang Bourgogne Franche Comté, Unité Mixte de Recherche 1098, Interactions Hôte-Greffon-Tumeur, Ingénierie Cellulaire et Génique, Besançon, France.
Sophie AupetUniversity Bourgogne Franche-Comté, INSERM, Etablissement Français du sang Bourgogne Franche Comté, Unité Mixte de Recherche 1098, Interactions Hôte-Greffon-Tumeur, Ingénierie Cellulaire et Génique, Besançon, France.
Caroline LaheurteÉtablissement Français du Sang Bourgogne Franche-Comté, Plateforme de BioMonitoring, Besançon, France.
Anne FrançoisEtablissement Français du Sang Ile-de-France, Ivry-Sur-Seine, France.
Eric ReschÉtablissement Hauts de France, Lille, France.
Frédéric BigeyÉtablissement Français du Sang Grand Est, Strasbourg, France.
Delphine BindaINSERM Centre Investigation Clinique 1431, Centre Hospitalier Universitaire (CHU) Besançon, Besançon, France.
Laurent BardiauxÉtablissement Français du Sang Pyrénées-Méditerranée, Toulouse, France.
Christian NaegelenÉtablissement Français du Sang Bourgogne Franche-Comté, Besançon, France.
Nadine MarpauxÉtablissement Français du Sang Bourgogne Franche-Comté, Besançon, France.
Fanny Angelot DelettreÉtablissement Français du Sang Bourgogne Franche-Comté, Besançon, France.
Philippe SaasUniversity Bourgogne Franche-Comté, INSERM, Etablissement Français du sang Bourgogne Franche Comté, Unité Mixte de Recherche 1098, Interactions Hôte-Greffon-Tumeur, Ingénierie Cellulaire et Génique, Besançon, France.
Pascal MorelÉtablissement Français du Sang Bourgogne Franche-Comté, Besançon, France.
Pierre TiberghienUniversity Bourgogne Franche-Comté, INSERM, Etablissement Français du sang Bourgogne Franche Comté, Unité Mixte de Recherche 1098, Interactions Hôte-Greffon-Tumeur, Ingénierie Cellulaire et Génique, Besançon, France.
Jacques LacroixService des Soins Intensifs Pédiatriques, Département de Pédiatrie, Université de Montréal, CHU Sainte-Justine, Montréal, QC, Canada; and.
Gilles CapellierService de reanimation, Centre Hospitalier Regional Universitaire Minjoz, Besançon, France.
Chrystelle VidalINSERM Centre Investigation Clinique 1431, Centre Hospitalier Universitaire (CHU) Besançon, Besançon, France.
Francine Garnache-OttouUniversity Bourgogne Franche-Comté, INSERM, Etablissement Français du sang Bourgogne Franche Comté, Unité Mixte de Recherche 1098, Interactions Hôte-Greffon-Tumeur, Ingénierie Cellulaire et Génique, Besançon, France.
Inserm · FRÉtablissement Français du Sang · FRCentre Hospitalier Universitaire de Besançon · FRCentre Hospitalier Universitaire Sainte-Justine · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Extracellular vesicles (EVs) are active components of red blood cell (RBC) concentrates and may be associated with beneficial and adverse effects of transfusion. Elucidating controllable factors associated with EV release in RBC products is thus important to better manage the quality and properties of RBC units. Erythrocyte-derived EVs (EEVs) and platelet-derived EVs (PEVs) were counted in 1226 RBC units (administered to 280 patients) using a standardized cytometry-based method. EV size and CD47 and annexin V expression were also measured. The effects of donor characteristics, processing methods, and storage duration on EV counts were analyzed by using standard comparison tests, and analysis of covariance was used to determine factors independently associated with EV counts. PEV as well as EEV counts were higher in whole-blood-filtered RBC units compared with RBC-filtered units; PEV counts were associated with filter type (higher with filters associated with higher residual platelets), and CD47 expression was higher on EEVs in RBC units stored longer. Multivariate analysis showed that EEV counts were strongly associated with filter type (P < .0001), preparation, and storage time (+25.4 EEV/µL per day [P = .01] and +42.4 EEV/µL per day [P < .0001], respectively). The only independent factor associated with PEV counts was the residual platelet count in the unit (+67.1 PEV/µL; P < .0001). Overall, processing methods have an impact on EV counts and characteristics, leading to large variations in EV quantities transfused into patients. RBC unit processing methods might be standardized to control the EV content of RBC units if any impacts on patient outcomes can be confirmed. The IMIB (Impact of Microparticles in Blood) study is ancillary to the French ABLE (Age of Transfused Blood in Critically Ill Adults) trial (ISRCTN44878718).

Indexed as

Blood PreservationExtracellular VesiclesAdultBlood TransfusionCritical IllnessErythrocytesHumans

Identifiers

PMID33166402
PMCPMC7656935
OpenAlexW3098767142

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.